Just like the 2020 resolution, Novartis AG’s $twenty five million 2016 civil resolution with the SEC worried poor sponsorships of HCPs to conferences and incorrect payments to HCPs to collect “healthcare information.” The fact that Novartis is currently facing a considerably more substantial—and prison—resolution for similar misconduct ou